

Oncology patients are vulnerable—and in the fight against infection, the dressing you use really matters. Tegaderm™ I.V. Port Dressings are specifically designed for implanted venous ports, offering both antimicrobial protection and the comfort your patients deserve.





3M™ Tegaderm™ I.V. Port Dressings

Patient Comfort: Adhesive-free window minimizes adhesive contact with patient skin

Antimicrobial Protection:

CHG gel pad provides immediate and continuous antimicrobial protection *1.2

Patient and Clinician Safety:

Adhesive-free window reduces risk of dressing sticking to needle during removal


Gentle and Strong:

Flexes with patient movement and can be worn up to 7 days

Easy Monitoring:

Transparent dressing and CHG gel pad permit clear visibility around the needle insertion site

- * Available with 3MTM TegadermTM CHG Chlorhexidine Gluconate I.V. Port Dressing
- ** In vitro testing shows that the transparent film provides a viral barrier from viruses 27 nm in diameter or larger while the dressing remains intact without leakage.



Accommodates a variety of non-coring Huber needles.

Documentation tape strip

- \cdot Preprinted for documenting dressing changes
- · Provides additional securement of tubing


Transparent film with adhesive-free window

- · Sterile barrier—protects against external contaminants including liquids, bacteria and viruses **
- · Highly breathable for moisture evaporation
- · Allows continuous observation around insertion site
- · Wear time up to 7 days

Reinforced stabilization border

Securement tape strip

- · Notched strip to seal dressing border and anchor tubing
- Film coating resists soiling and protects against external contaminants



Chlorhexidine gluconate (CHG) gel pad*

- Provides immediate and continuous protection against microorganisms associated with CRBSIs^{1,2}
- · Designed to conform around the needle—stays in place and in contact with skin
- Remains clear and protects even in the presence of blood, saline and exudates

Ordering Information

PRODUCT NAME	PRODUCT CODE	SIZE	EACH/ BOX	BOXES/ CASE	HCPCS CODE
3M [™] Tegaderm [™] CHG Chlorhexidine Gluconate I.V. Port Dressing	1665	CHG gel pad device 2 1/16 in. x 1 15/16 in. 6,2 cm x 4,9 cm Dressing 4 3/4 in. x 4 3/4 in. 12 cm x 12 cm	25 dressings + devices/box	4 boxes/ case	A6268
3M [™] Tegaderm [™] I.V. Transparent Film Dressing with Adhesive-Free Window	1668	Dressing 4 ¾ in. x 4 ¾ in. 12 cm x 12 cm	25 dressings/ box	4 boxes/ case	A6268

Disclaimer

HCPCS codes have been provided to assist you in the preparation of insurance claims. Please note, however, that the reimbursement information provided by 3M Health Care and its representatives is intended to provide general information relevant to coverage and coding for 3M products. Insurers' reimbursement policies can vary and the use of the codes discussed here does not guarantee that an insurer will cover or pay at any particular level. Health care providers should exercise independent clinical judgment in choosing the codes which most accurately describe the products provided.

To learn more, visit **3M.com/TegadermIVPortDressings**, contact your 3M Critical & Chronic Care Solutions representative, or call the 3M Health Care Customer Helpline at **1-800-228-3957**. Outside of the United States, contact the local 3M subsidiary.



Critical & Chronic Care Solutions Division 3M Health Care

2510 Conway Avenue St. Paul, MN 55144 USA 1 800 228-3957 3M.com/C3SD

Please recycle. Printed in U.S.A.

© 3M 2015. All rights reserved.

3M and Tegaderm are trademarks of 3M. Used under license in Canada.

70-2011-5667-9

¹ Hensler J (2009). Growth inhibition of microorganisms involved in CA-infections by an antimicrobial transparent I.V. dressing containing CHG. European Society of Clinical Microbiology and Infectious Diseases, May 2009.

²Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-related Infections. Healthcare Infection Control Practices Advisory Committee (HICPAC); (Appendix 1). Clin Infect Dis, 2011; 52(9):e162.